Therapeutic interventions aimed at cccDNA: unveiling mechanisms and evaluating the potency of natural products
Authors:
Open Access
- 17 June 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 15, 1598872
Abstract
Hepatitis B virus (HBV) infection persists as a formidable global health predicament, imposing a substantial burden on public health. It not only elevates the risk of cirrhosis but also significantly heightens the incidence of hepatocellular carcinoma (HCC), thereby exacerbating the complexity of managing this disease. Central to the intractability of chronic hepatitis B is the tenacious persistence of covalently closed circular DNA (cccDNA) within the nuclei of infected hepatocytes. This cccDNA serves as a stable transcriptional template, continuously fueling the production of viral components and rendering the virus refractory to current antiviral interventions. The attainment of a definitive cure for HBV infection hinges upon the development of innovative antiviral strategies that can precisely and effectively target and eliminate cccDNA from the infected liver cells. In this regard, natural products have emerged as a promising source of potential therapeutics. This comprehensive review delves into the natural products that have shown promise in specifically targeting cccDNA. It meticulously elucidates the intricate molecular mechanisms through which these natural compounds modulate cccDNA activity, such as interfering with cccDNA formation, disrupting its epigenetic regulation, or inhibiting its transcriptional output. Developing innovative strategies to target and eliminate cccDNA is crucial for curing HBV infection, and natural products hold great promise. This review details several natural products with cccDNA-targeting potential, supported by clear mechanisms and data. Dehydrocheilanthifolin (DHCH) from Corydalis saxicola inhibits HBsAg and HBeAg secretion in HepG2.2.15 cells. It may disrupt viral processes like pgRNA packaging or DNA polymerase activity, with IC50 values for reducing extracellular, intracellular DNA, and cccDNA at 15.08 μM, 7.62 μM, and 8.25 μM respectively. Methyl helicterate from Helicteres angustifolia decreases HBsAg, HBeAg, HBV DNA, and cccDNA in HepG2.2.15 cells. 15.8 μM reduces intracellular cccDNA. Curcumin from turmeric reduces viral load and cccDNA in d-imHCs; 30µM halves cccDNA levels. Epigallocatechin gallate (EGCG) from green tea hinders viral transcription and replication. 22.9μg/ml EGCG lowers cccDNA by about 60%. Asiaticoside from Hydrocotyle sibthorpioides inhibits HBsAg, HBeAg, and cccDNA in HepG2.2.15 cells. Notably, despite extensive research, no natural product has yet obtained clinical validation for cccDNA clearance, highlighting the significant translational gap between pre-clinical research and clinical application. By elucidating these molecular mechanisms, this review aims to contribute to the development of HBV-targeted therapies, offering valuable insights for designing novel therapeutic agents and optimizing existing treatment regimens, ultimately advancing the quest for an effective cure for HBV infection.Keywords
This publication has 90 references indexed in Scilit:
- Sphondin efficiently blocks HBsAg production and cccDNA transcription through promoting HBx degradationJournal of Medical Virology, 2023
- SIRT3 restricts hepatitis B virus transcription and replication through epigenetic regulation of covalently closed circular DNA involving suppressor of variegation 3‐9 homolog 1 and SET domain containing 1A histone methyltransferasesHepatology, 2018
- Hepatitis B virus X protein–elevated MSL2 modulates hepatitis B virus covalently closed circular DNA by inducing degradation of APOBEC3B to enhance hepatocarcinogenesisHepatology, 2017
- PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidationHepatology, 2017
- A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D virusesHepatology, 2015
- Antiviral activity of methyl helicterate isolated from Helicteres angustifolia (Sterculiaceae) against hepatitis B virusAntiviral Research, 2013
- The role of antioxidant versus pro‐oxidant effects of green tea polyphenols in cancer preventionMolecular Nutrition & Food Research, 2011
- Green tea extract and its major component epigallocatechin gallate inhibits hepatitis B virus in vitroAntiviral Research, 2008
- Alkaloids from Corydalis saxicola and Their Anti‐Hepatitis B Virus ActivityChemistry & Biodiversity, 2008
- Two distinct segments of the hepatitis B virus surface antigen contribute synergistically to its association with the viral core particles 1 1Edited by J. KarnJournal of Molecular Biology, 1999